The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of PAK4 expression with overall survival in patients with non-small cell lung cancer (NSCLC).
 
Hirva Mamdani
Consulting or Advisory Role - MorphoSys (I); Seagen (I); Zentalis
 
Sharon Wu
Employment - Caris Life Sciences
Research Funding - Caris Life Sciences
 
Erin Morgan
Employment - Caris Life Sciences
 
Husain Yar Khan
No Relationships to Disclose
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AstraZeneca; Naveris
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Dipesh Uprety
No Relationships to Disclose
 
Sonam Puri
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst)
 
Hina Khan
Consulting or Advisory Role - Genzyme
Research Funding - Bristol Myers Squibb Foundation
 
Luis E. Raez
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); NantHealth (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; Guardant Health; HUYA Bioscience International; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Balasz Halmos
No Relationships to Disclose
 
Patrick C. Ma
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences
Speakers' Bureau - AstraZeneca; Merck
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EpicentRx (Inst); Loxo (Inst); Merck (Inst); Tesaro (Inst)
 
Gilberto Lopes
Stock and Other Ownership Interests - Lucence Diagnostics; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Asfar S. Azmi
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Inc
Research Funding - Karyopharm Therapeutics